Aims To characterize milk/plasma (M/P) ratio and infant dose, for fluoxetine and norfluoxetine, in breast-feeding women taking fluoxetine for the treatment of depression, and to determine the plasma concentration of these drugs in their infants. Methods Fourteen women (mean age 32.2 years) taking fluoxetine (mean dose 0.51 mg kg −1 day −1 ) and their infants (mean age 3.4 months) were studied. Fluoxetine and norfluoxetine in plasma and milk were measured by high-performance liquid chromatography over a 24 h dose interval in four patients, and by single point data collection in 10 patients. Infant exposure was estimated as the product of estimated milk production, and average drug concentration in milk, normalized to body weight and expressed as a percentage of the weight-adjusted maternal dose. Results Mean M/P values of 0.68 (95% CI 0.52-0.84) and 0.56 (95% CI 0.35-0.77) were calculated for fluoxetine and norfluoxetine, respectively. Mean total infant exposure (fluoxetine equivalents) was estimated to be 6.81% (range 2.15-12%) of the weight-adjusted maternal dose of fluoxetine. Contributions from fluoxetine and norfluoxetine were approximately equal. Fluoxetine (range 20-252 mg l −1 ) was detected in five of the nine infants from whom samples were collected, and norfluoxetine (range 17-187 mg l −1 ) was detected in seven of the nine infants. The highest of these concentrations was about 70% of the maternal plasma concentrations.
similar potency as a serotonin reuptake inhibitor [2] .
Introduction
However, published data on the transfer of these drugs into human milk and their effects in breast-fed infants It is important to know the extent of drug transfer into human milk in order to assess the safety of breastfeeding are limited to 18 cases described in six reports [3] [4] [5] [6] [7] [8] . In the present study, the transfer of fluoxetine and norfluox-during maternal ingestion of the drug. Depressive disorders are common, both during the antenatal period etine into milk has been quantified in 14 lactating women and related to adverse effects and plasma concentrations and in the early months after childbirth [1] . Fluoxetine, a selective serotonin reuptake inhibitor, is widely used to in their breast-fed infants. treat depression in this period. The drug is metabolized to norfluoxetine which has a much longer half-life and a Methods Correspondence: Mrs J. H. Kristensen, Department of Pharmacy, King Edward 44-85 kg) and their infants (7 M and 7 F; mean age Materials 3.4 months, range 0.1-15 months; mean body weight 5.25 kg, range 2.8-10 kg) were enrolled in the study.
Fluoxetine hydrochloride and norfluoxetine maleate standards were donated by Eli Lilly Australia Pty Ltd, and The median dose of fluoxetine ingested by the women was 0.51 (range 0.24-0.94) mg kg −1 day −1 , representing amitriptyline hydrochloride by Merck Sharp and Dohme (Australia) Pty Ltd. All solvents and other chemicals were an absolute dose range of 20-80 mg daily. Therapy with fluoxetine had commenced a median of 70 (range of analytical or h.p.l.c. grade. 13-750) days prior to the study day, and all participants were considered to be at steady-state at the time of study.
High performance liquid chromatography (h.p.l.c.)
Following the addition of amitriptyline (200 ng ) as an internal standard, 1 ml aliquots of plasma were made Study protocol alkaline with 0.2 ml of 1 m NaOH and the analytes were The study design was approved by the Research and extracted into 10 ml 1% isoamylalcohol in hexane by Ethics Committees of King Edward Memorial/Princess shaking vigorously for 5 min. After centrifugation (2000 g Margaret and Christchurch Hospitals, and written for 5 min), the organic phase (9 ml) was back-extracted informed consent was obtained from all participants. into 0.2 ml 0.05 m HCl by vortex mixing for 1 min, and 0.05-0.1 ml aliquots of the acid phase were injected into the h.p.l.c. Milk samples were extracted in a similar Data collection-limited sampling protocol manner except that the method of addition was used to enable correction for differing recoveries that may arise Ten mothers were enrolled in this arm of the study. A because of variable matrix composition. Rac-fluoxetine breast milk sample (15 ml) was collected by manual and rac-norfluoxetine concentrations in milk were deterexpression or by breast pump, immediately prior to a mined by taking four equal aliquots of each milk sample feed ( prefeed) and also at the end ( postfeed) of the same (1 ml) and spiking three of these aliquots with increasing feed. A maternal blood sample (10 ml) was collected by concentrations of authentic fluoxetine and norfluoxetine. venepuncture at the time of the postfeed milk sample.
The samples were then extracted and analysed as for The mean time between the blood sample and last dose plasma. The h.p.l.c. system consisted of a Beckman was 5.8 h (range 1.1-23.5). Six of these women gave Ultrasphere C8 column (250×4.6 mm) and a solvent of consent for a venous blood sample (0.5-1 ml, heparinized) 40% acetonitrile containing 0.09% sodium 1-octaneto be taken from their infant; this was taken immediately sulphonic acid and 0.01% NNNN-tetramethylethylene after the maternal blood sample.
diamine (final pH adjusted to 2.5 using H 3 PO 4 ). Eluting compounds were detected by their u.v. absorbance at 230 nm. Plasma fluoxetine and norfluoxetine concen-Data collection-intensive sampling protocol trations were interpolated from a standard curve ( peak height ratio analyte: amitriptyline vs analyte concentration Four women in this arm of the study were admitted to the research ward at 07.30 h, and had a venous catheter (r 2 >0.995) run with each batch of samples. For each individual milk sample, a standard curve ( peak height inserted into a forearm vein immediately prior to the morning dose of fluoxetine at 08.00 h. Venous blood ratio analyte: amitriptyline vs added analyte concentration (r 2 >0.995) was constructed and drug concentrations samples (8 ml, heparinized) were collected from the catheter at 0, 1, 2, 3, 4, 6 and 8 h postdose, and also by were determined from the negative x-axis intercept. The intraday coefficients of variation (CV; n=5) for the venepuncture at 12 and 24 h. At the same time intervals, both breasts were emptied via an electric or manual plasma assay were 3.3 and 1.5% at 25 and 500 mg l −1 , respectively, for fluoxetine, and 4.8 and 1.9% at 25 and breast pump. Samples of milk (15 ml) were retained for drug assay and the remainder made available to bottle 500 mg l −1 , respectively, for norfluoxetine. The interday coefficients of variation (n=15) for the plasma assay were feed their infants. The women were discharged from hospital after 8 h and milk and plasma samples at 12 and 3.8 and 2.0% at 25 and 500 mg l −1 , respectively, for fluoxetine, and 7.7 and 4.1% at 25 and 500 mg l −1 , 24 h postdose were collected at the patient's home. Three of these women gave consent for a venous blood sample respectively, for norfluoxetine. For the milk assay intraday CVs (n=4) were 3.4 and 5.0% at 25 and 500 mg l −1 , (0.5-1 ml, heparinized) to be taken from their infants.
For all studies, infant health and wellbeing were respectively, for fluoxetine, and 5.0 and 5.1% at 25 and 500 mg l −1 , respectively, for norfluoxetine. For the milk evaluated by enquiry of the mother and/or paediatrician and by checking the infant's achievement of normal assay interday CVs (n=12) were 4.1 and 5.0% at 25 and 500 mg l −1 , respectively, for fluoxetine, and 5.4 and 5.6% developmental milestones. at 25 and 500 mg l −1 , respectively, for norfluoxetine. The limit of quantification for both analytes in milk and plasma was 15 mg l −1 .
Statistical evaluation of data
Data have been summarized as mean (95% CI) unless otherwise specified. Differences between means were assessed using Student's t-test for paired or independent data groups. Area under the plasma and milk concentration-time profiles (AUC(0,24h)) was calculated using the log trapezoidal rule.
Calculation of infant dose
The absolute infant dose of fluoxetine or norfluoxetine calculated as fluoxetine equivalents was determined by two different methods, both assuming an oral availability of 100% and an average infant milk intake of 0.15 l kg −1 day −1 [9]. For the limited sampling protocol, the milk concentration was taken as the mean of the preand post-feed milk concentrations, while for the intensive sampling protocol the average milk concentration (AUC milk /24 h dose interval) was used. This value was multiplied by the average milk intake of 0.15 l kg −1 day −1 [9] to give a weight-adjusted estimate of daily infant dose. For both methods, the infant dose and plasma concentration data and milk to plasma ratio (M/P) for all 14 patients are summarized in Table 1 . For concentrations were significantly ( paired t-test, P<0.05) higher in the post-feed than in the pre-feed milk. the limited sampling group, mean M/P was 0.74 (0.53-0.95) for fluoxetine and 0.62 (0.42-0.82) for Table 2 summarizes the maternal daily dose of fluoxetine and duration of therapy, the calculated infant norfluoxetine. Corresponding M/Ps for the intensive sampling group were 0.52 (0.32-0.72) and 0.41 doses of fluoxetine and norfluoxetine (as fluoxetine equivalents) together with the age of the infant at the (0.18-0.64), respectively. Although the mean M/P was higher with the limited sampling approach, the difference time of the study. Calculated infant doses were 3.36 (2.38-4.34)% for fluoxetine and 3.45 (2.46-4.44)% for was not statistically different, albeit with a suboptimal power of study. For all patients combined, mean M/P norfluoxetine giving a mean total infant exposure of 6.81% of the weight-adjusted maternal dose. ratio was 0.68 (0.52-0.84) for fluoxetine and 0.56 (0.35-0.77) for norfluoxetine.
Blood samples were collected from nine infants in the study. Fluoxetine was detected in plasma from five The limited sampling protocol also afforded an opportunity to assess differences in drug concentra-infants and norfluoxetine in seven infants (Table 2) . Norfluoxetine concentration generally was highest in tions between the pre-and post-feed milk samples. Both fluoxetine ( pre-feed 98 (15-181) mg l −1 , post-feed 164 infants aged 1.5 months or lower (infants 10,12,13,14) compared with older infants (infants 2,4,11). However, (48-279) mg l −1 ) and norfluoxetine ( pre-feed 88 (19-157) mg l −1 , post-feed 164 (68-260) mg l −1 ) mean it is important to note that all of these infants (infants Table 1 Plasma and milk concentrations and M/P ratios for fluoxetine and norfluoxetine. Milk and plasma concentrations from a limited sampling protocol with plasma concentration from a single sample and milk concentration from the mean of pre-and post-feed concentrations.
Fluoxetine Norfluoxetine
10,12,13,14) were exposed to fluoxetine in utero. The Discussion long half-lives of both fluoxetine and norfluoxetine would suggest that a large contribution to these concen-Measurement of M/P and infant exposure to drugs in human milk is generally most robust when an intensive trations derived from the in utero exposure.
A detailed history of infant wellbeing and progress was AUC sampling protocol is utilized [10] . In the present study M/P for the limited sampling protocol was higher obtained for the four infants in the intensive sampling arm of the study. Two of the four had no symptoms that and more variable than for the intensive sampling approach. Nevertheless, variability with the limited might be considered fluoxetine-related, and had achieved normal developmental milestones. Infant 1 was described sampling protocol may have been minimized by the long half-lives of fluoxetine (1-4 days) and norfluoxetine as having colic by her mother. Infant 3 had colic at the age of 2-4 months but was well at the time of study (7-15 days) [2]. Drug concentrations measured in milk from the limited sampling showed significantly greater (15 months). She was also reported as always having been hyperactive. The infants enrolled in the limited sampling concentrations in postfeed compared with prefeed milk. The difference is likely to be due to the increase in collection arm of the study were also assessed for achievement of weight-for-age milestones and by inter-lipid concentration that occurs during a feed [11] together with the relatively high lipid solubility of fluoxetine (log viewing the mother and/or her paediatrician. Infants 10 and 14 were referred for study because of 'withdrawal P octanol5buffer pH 7.4=1.988) and norfluoxetine (log P octanol5buffer pH 7.4=1.82). The finding also suggests symptoms' (uncontrollable crying, irritability and poor feeding ) that were consistent with high plasma concen-that protocols using only a single milk sample for lipid soluble drugs will be associated with increased variability trations of norfluoxetine and/or fluoxetine, and their recent in utero exposure to the drug and its metabolite in M/P and infant dose. Mean M/P for fluoxetine and norfluoxetine were 0.68 (Table 2) . However, for infant 14 maternal methadone use may have been a contributing factor. These two cases and 0.56, respectively, suggesting a modest potential for penetration into breast milk. However, the resultant mean also had high values for infant dose via breast milk and this may have contributed to the symptoms observed.
concentrations of fluoxetine and norfluoxetine in milk were 131 and 210 mg l −1 , respectively, translating to a No adverse effects were reported for the other eight infants in this arm of the study. All of these infants had mean infant dose exposure of 3.36% for fluoxetine and 3.45% for norfluoxetine. In a previous study, Taddio body weights within the normal range.
Table 2
Maternal dose, duration of therapy, infant age, plasma concentration of fluoxetine and norfluoxetine and estimated dose. and 100% at about 6 months of age [14] , the potential for adverse effects from fluoxetine therapy either during norfluoxetine) as a mean of 10.8% of the maternal dose (infant daily milk intake assumed to be 1 l). However, pregnancy and/or during breast-feeding is expected to be greatest in preterm neonates as well as during the first recalculation of this exposure using the widely accepted milk intake of 0.15 l kg −1 day −1 [9] gave a value of 1-2 weeks of life for full-term infants.
In breast-fed infants, the calculated mean total dose of infant exposure of 6.4% [12] . This compares well with our mean dose exposure of 6.8% for fluoxetine plus fluoxetine and its metabolite norfluoxetine of 6.8% of the weight-adjusted maternal dose is less than the 10% norfluoxetine and with the range of 3-10% reported in four patients by Yoshida et al. [8] .
level of concern proposed by Begg et al. [14] . It should be noted that there was considerable interpatient varia-The question of adverse effects in infants due to the ingestion of fluoxetine via breast milk is controversial.
bility in the estimated dose with five of our infant doses being in the range 8.6-12%. Our study, and results from Both Taddio et al. [6] and Yoshida et al. [8] reported no adverse effects in their series of 10 and 4 patients, others [6, 8] indicate that many infants will tolerate these levels of exposure through breast milk. However, because respectively. Burch & Wells [4] also reported a single case with no adverse effects and milk fluoxetine concen-of the variability in infant dose, and because the drug and its metabolite were detected in infant plasma (especially trations of 17-67 mg l −1 and norfluoxetine concentrations of 13-52 mg l −1 . However, Isenberg described irritability high concentrations in young infants), caution should be exercised at all times, and particularly during the early in a breast-fed 5 month old infant [3] . Milk concentrations of fluoxetine and norfluoxetine were 29 mg l −1 and neonatal period. Special consideration should be given to infants who are additionally exposed to fluoxetine in 42 mg l −1 , respectively. Colic has been reported in an infant exposed to similar amounts of fluoxetine via breast utero. The long-term effects of fluoxetine/norfluoxetine exposure via breast milk have not been studied. However, milk [5] . Milk drug concentrations were not measured, but analysis of this infant's plasma showed 340 mg l −1 of studies of infants exposed to fluoxetine during pregnancy, have shown that neurodevelopment was normal [15, 16]. fluoxetine and 208 mg l −1 of norfluoxetine. Brent & Wisner described a single case of seizure-like episodes in a breast-fed infant whose mother had taken fluoxetine
